# Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer

> **NCT04163237** · PHASE3 · UNKNOWN · sponsor: **Guangxi Medical University** · enrollment: 50 (estimated)

## Conditions studied

- Advanced Liver Cancer

## Interventions

- **DRUG:** PD-1
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT04163237
- **Lead sponsor:** Guangxi Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-01
- **Primary completion:** 2020-10-31
- **Final completion:** 2020-11-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2019-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04163237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04163237, "Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04163237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*